Department of Radiology, Taipei Veterans General Hospital, Taipei, Taiwan.
School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
J Neurointerv Surg. 2023 Dec 19;16(1):73-80. doi: 10.1136/jnis-2022-019957.
To investigate the technical safety and outcome of in-stent restenosis (ISR) prevention with drug-eluting balloon (DEB) in patients with postirradiated carotid stenosis (PIRCS) undergoing percutaneous angioplasty and stenting (PTAS).
Between 2017 and 2021, we prospectively recruited patients with severe PIRCS for PTAS. They were randomly separated into two groups based on endovascular techniques performed with and without DEB. Preprocedural and early postprocedural (within 24 hours) MRI, short-term ultrasonography (6 months after PTAS), and long-term CT angiography (CTA)/MR angiography (MRA), 12 months after PTAS, were performed. Technical safety was evaluated based on periprocedural neurological complications and the number of recent embolic ischemic lesions (REIL) in the treated brain territory on diffusion-weighted imaging of early postprocedural MRI.
Sixty-six (30 with and 36 without DEB) subjects were enrolled, with one failure in techniques. For 65 patients in the DEB versus conventional groups, technical neurological symptoms within 1 month (1/29 (3.4%) vs 0/36; P=0.197) and REIL numbers within 24 hours (1.0±2.1 vs 1.3±1.5; P=0.592) after PTAS showed no differences. Peak systolic velocity (PSVs) on short-term ultrasonography was significantly higher in the conventional group (104.13±42.76 vs .81.95±31.35; P=0.023). The degree of in-stent stenosis (45.93±20.86 vs 26.58±8.75; P<0.001) was higher, and there were more subjects (n=8, 38.9% vs 1, 3.4%; P=0.029) with significant ISR (≥ 50%) in the conventional group than in the DEB group on long-term CTA/MRA.
We observed similar technical safety of carotid PTAS with and without DEBs. The number of cases of significant ISR were fewer and the degree of stenosis of ISR was less in primary DEB-PTAS of PIRCS than for conventional PTAS in the 12-month follow-up.
研究药物洗脱球囊(DEB)在接受经皮血管成形术和支架置入术(PTAS)的放射性颈动脉狭窄(PIRCS)患者中预防支架内再狭窄(ISR)的技术安全性和结果。
2017 年至 2021 年,我们前瞻性招募了严重 PIRCS 患者进行 PTAS。根据是否使用 DEB 将患者随机分为两组。在 PTAS 后即刻(24 小时内)进行 MRI 和短期超声检查,在 PTAS 后 6 个月进行 CT 血管造影(CTA)/磁共振血管造影(MRA),在 PTAS 后 12 个月进行。根据治疗大脑区域弥散加权成像上即刻术后 MRI 的围手术期神经并发症和最近栓塞性缺血性病变(REIL)的数量评估技术安全性。
共纳入 66 例患者(DEB 组 30 例,常规组 36 例),其中 1 例技术失败。在 DEB 组和常规组的 65 例患者中,PTAS 后 1 个月内的技术神经症状(1/29(3.4%)vs. 0/36;P=0.197)和 24 小时内的 REIL 数量(1.0±2.1 vs. 1.3±1.5;P=0.592)无差异。短期超声检查的收缩期峰值速度(PSV)在常规组中明显较高(104.13±42.76 vs. 81.95±31.35;P=0.023)。支架内狭窄程度(45.93±20.86 vs. 26.58±8.75;P<0.001)较高,常规组中有更多(n=8,38.9%)与 DEB 组(n=1,3.4%)相比,有明显的支架内再狭窄(≥50%)(P=0.029)。
我们观察到在 PIRCS 患者的颈动脉 PTAS 中,DEB 的使用与不使用在技术安全性方面相似。在 12 个月的随访中,原发性 DEB-PTAS 的严重 ISR 病例较少,ISR 的狭窄程度较轻。